Literature DB >> 698031

Direct measurement of propranolol bioavailability during accumulation to steady-state.

A J Wood, K Carr, R E Vestal, S Belcher, G R Wilkinson, D G Shand.   

Abstract

1. A high performance liquid chromatographic method for the determination of propranolol in human plasma and blood has been developed and used to confirm that cumulation occurred during chronic oral administration, steady-state being achieved within 48 h of beginning 80 mg of the drug every 8 h. 2. The method was adapted to measure [H3]-propranolol and native drug in the same blood sample and was applied to determine simultaneously the disposition of i.v. ([H3]-propranolol) and orally (non-labelled) administered drug after single oral dose of 80 mg and when steady-state had been established on an 80 mg, 8-hourly regimen. 3. Using this approach it was possible to show that a reduced oral clearance at steady-state was associated with a smaller reduction in systemic (i.v.) clearance and no change in liver blood flow. A direct estimate of bioavailability was also possible and was found to be increased at steady-state compared with a single oral dose. 4. We conclude that the accumulation of propranolol during the attainment of steady-state is due to a reduction in intrinsic clearance, resulting in reduced presystemic hepatic extraction.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698031      PMCID: PMC1429476          DOI: 10.1111/j.1365-2125.1978.tb00862.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Contribution of the liver to overall elimination of propranolol.

Authors:  C F George; M L Orme; P Buranapong; D Macerlean; A M Breckenridge; C T Dollery
Journal:  J Pharmacokinet Biopharm       Date:  1976-02

3.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  A sensitive gas chromatographic method for the determination of propranolol in human plasma.

Authors:  E Di Salle; K M Baker; S R Bareggi; W D Watkins; C A Chidsey; A Frigerio; P L Morselli
Journal:  J Chromatogr       Date:  1973-09-26

5.  The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol.

Authors:  A S Nies; G H Evans; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

6.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues.

Authors:  T Walle
Journal:  J Pharm Sci       Date:  1974-12       Impact factor: 3.534

  8 in total
  39 in total

Review 1.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.

Authors:  D Bach; R Blevins; N Kerner; M Rubenfire; D J Edwards
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

4.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.

Authors:  S L Bowman; S A Hudson; G Simpson; J F Munro; J A Clements
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

Review 6.  Drug kinetics and hepatic blood flow.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

8.  The assessment of bioavailability in the presence of nonlinear elimination.

Authors:  S D Hall; C B McAllister; G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

9.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

Review 10.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.